Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates regarding the acquisition by PathLabs Unifiers Private Limited, a Wholly Owned Subsidiary, of the remaining 30% equity stake in Centrapath Labs Private Limited, a Subsidiary of PathLabs Unifiers Private Limited. The acquisition has made Centrapath Labs Private Limited a Wholly Owned Subsidiary of PathLabs Unifiers Private Limited.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about making a further investment in PathLabs Unifiers Private Limited, a Wholly Owned Subsidiary, by subscribing to its equity shares on October 12, 2026. The disclosure is as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance under Regulation 74(5) for the quarter ended September 30, 2026.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates, specifically an intimation of Income Tax appeal filed by the Income Tax Department before the Income Tax Appellate Tribunal, New Delhi against the order of Assessment year 2022-23 under section 250 of the Income Tax Act, 1961.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has completed the acquisition of a stake in SN Genelab Private Limited as per the terms and conditions of the Agreement.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, as per the agreement and prevailing provisions in Ghana. This makes SHL a step-down subsidiary of the Company.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the Board meeting on November 04, 2026, to consider un-audited financial results for the quarter and half year ending September 30, 2026.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has acquired a 70% stake in SN Genelab Private Limited (S N Gene) for up to INR 168 Crores, with the transaction expected to be completed by November 30, 2026.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on September 24, 2026, where the Board of Directors approved the acquisition of 70% stake in SN Genelab Private Limited (SN Gene) from its existing Shareholders.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about a copy of newspaper publication regarding unclaimed equity shares due for transfer to the Investor Education and Protection Fund (IEPF) and notice to shareholders for the 11th Annual General Meeting (AGM) of Digjam Limited.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about the completion of subscription of 30% stake in Neuome Technologies Private Limited by its wholly-owned subsidiary Dr. Lal Ventures Private Limited.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has incorporated a step-down subsidiary company, Dr. Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, with its wholly-owned subsidiary Dr. Lal PathLabs FZCO subscribing to 70% of its share capital.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange regarding the allotment of 211050 shares under the Dr. Lal PathLabs Employee Stock Option Plan 2022. The paid-up equity share capital of the company has increased to INR 1,67,84,88,200 divided into 16,78,48,820 equity shares of INR 10/- each.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about the Transcript of Q1 & FY27 Earnings Conference Call. The company's revenue for Q1 FY27 was Rs. 798 crore, registering a year-on-year growth of 19.1%. The revenue growth is mainly driven by Patient volumes and sample volumes.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange regarding Change in Director(s) of the company. Mr. Gurinder Singh Kalra has completed his current tenure as an Independent Director of the company on July 26, 2026, and consequently ceases to be an Independent Director of the company.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has submitted the Exchange a copy Scrutinizers report of the Annual General Meeting held on July 25, 2026. The company has informed the Exchange regarding voting results.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. held its 32nd Annual General Meeting on July 25, 2026, through video conferencing. The meeting was attended by 65 members, including 3 promoters and 62 public shareholders. The company's financial statements for the year ended March 31, 2026, were adopted, and a final dividend of INR 4 per share was declared. The remuneration structure of the executive chairman and whole-time director, (Hony) Brig Dr. Arvind Lal, was revised, and he was re-appointed for a five-year term. Dr. Vandana Lal's remuneration structure was also revised.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about the publication of a newspaper advertisement regarding its financial results for the quarter ended June 30, 2026.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has made the audio recording of its Q1 FY27 earnings conference call with investors and analysts available on its website.

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation for Q1 FY2027 un-audited financial results.